The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Coffee and caffeine are speculated to be associated with the reduced risk of Parkinson’s disease (PD). The present study aimed to investigate the disease-modifying potential of caffeine on PD, either for healthy people or patients, through a meta-analysis. The electronic databases were searched using terms related to PD and coffee and caffeinated food products. Articles were included only upon fulfillment of clear diagnostic criteria for PD and details regarding their caffeine content. Reference lists of relevant articles were reviewed to identify eligible studies not shortlisted using these terms. In total, the present study enrolled 13 studies, nine were categorized into a healthy cohort and the rest into a PD cohort. The individuals in the healthy cohort with regular caffeine consumption had a significantly lower risk of PD during follow-up evaluation (hazard ratio (HR) = 0.797, 95% CI = 0.748–0.849, p < 0.001). The outcomes of disease progression in PD cohorts included dyskinesia, motor fluctuation, symptom onset, and levodopa initiation. Individuals consuming caffeine presented a significantly lower rate of PD progression (HR = 0.834, 95% CI = 0.707–0.984, p = 0.03). In conclusion, caffeine modified disease risk and progression in PD, among both healthy individuals or those with PD. Potential biological benefits, such as those obtained from adenosine 2A receptor antagonism, may require further investigation for designing new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
From Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis (2020) · cites this paper as [219]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“Caffeine is an adenosine A2A receptor antagonist [8].”
BackgroundLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821 · cited 1×
“However, responses to one-night washout are variable, and the effect of levodopa may last for 2 weeks [43].”
BackgroundEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199 · cited 1×
“Risk factors for PD include genetic mutations, environmental toxins, and lifestyle [1].”
BackgroundA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901 · cited 1×
“Moreover, if the intervention itself causes certain symptomatic effects in conjunction, similar to rasagiline or caffeine, it would be challenging to distinguish between disease modification and symptomatic effect [44].”
BackgroundPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“[17] USA Health Professionals’ Follow-Up Study and Nurses’ Health Study (1976 and 1986/1994) 135,916 Semiquantitative food-frequency questionnaire (SFFQ) Caffeine was 137 mg per cup of coffee, 47 mg per cup of tea, 46 mg per can or bottle of cola beverage, and 7 mg per serving of chocolate candy.”
BackgroundNeuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Cited by
Ikram, M. A., Park, T. J., Ali, T., & Kim, M. O. (2020) · Antioxidants · doi:10.3390/antiox9090902 · Cited by 170
Schiess, N., Cataldi, R., Okun, M. S., Fothergill‐Misbah, N., Dorsey, E. R., Bloem, B. R., Barretto, M., Bhidayasiri, R., Brown, R. J., Chishimba, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1783 · Cited by 158
Caffeine and Its Antioxidant Properties—It Is All about Dose and Source
Ősz, B.-E., Jîtcă, G., Ștefănescu, R., Puşcaş, A., Tero-Vescan, A., & Vari, C.-E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113074 · Cited by 177
Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis
Iriondo-DeHond, A., Uranga, J. A., del Castillo, M. D., & Abalo, R. (2020) · Nutrients · doi:10.3390/nu13010088 · Cited by 126
“As mentioned for caffeine, CA and CGA are coffee components with antioxidant properties and neuroprotective effects against dopaminergic neurotoxicity [216,217] that have been suggested to underlie the decrease in PD risk associated with coffee consumption [218,219].”
BackgroundThe Role of Diet and Dietary Patterns in Parkinson’s Disease
Knight, E., Geetha, T., Burnett, D. O., & Babu, J. R. (2022) · Nutrients · doi:10.3390/nu14214472 · Cited by 111
“A metaanalysis observed that caffeine consumption typically from coffee is inversely related to PD risk and progression [51].”
BackgroundLinking environmental risk factors with epigenetic mechanisms in Parkinson’s disease
Tsalenchuk, M., Gentleman, S., & Marzi, S. J. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00568-z · Cited by 105
“Coffee drinking is also associated with a lower risk for both disease risk and progression 53 .”
BackgroundJenner, P. G., Mori, A., Aradi, S. D., & Hauser, R. A. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1880896 · Cited by 96
Angelopoulou, E., Paudel, Y. N., Papageorgiou, S. G., & Piperi, C. (2022) · Brain Sciences · doi:10.3390/brainsci12020175 · Cited by 79
“Given the protective role of coffee against LID development and PD progression [158], and the neuroprotective effects of caffeine on 6-OHDA-lesioned rat models of PD via histone deacetylase inhibition [159], histone deacetylation could be hypothesized to underlie the protective role of coffee in this case.”
BackgroundEpidemiology of Parkinson’s Disease: An Update
Deliz, J. R., Tanner, C. M., & González-Latapí, P. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01339-w · Cited by 90
“Nonetheless, the effect of caffeine on progression of motor symptoms relating to PD remains challenging to fully understand [99].”
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota
Yemula, N., Dietrich, C. M., Dostal, V., & Hornberger, M. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212707 · Cited by 75
Coffee and Caffeine Consumption for Human Health
Abalo, R. (2021) · Nutrients · doi:10.3390/nu13092918 · Cited by 59
“could not determine the optimal daily dosage or food source of caffeine [7].”
BackgroundBehl, T., Madaan, P., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., Chigurupati, S., Alrashdi, I., & BUNGAU, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810161 · Cited by 63
Methylxanthines and Neurodegenerative Diseases: An Update
Janitschke, D., Lauer, A. A., Bachmann, C. M., Grimm, H. S., Hartmann, T., & Grimm, M. O. W. (2021) · Nutrients · doi:10.3390/nu13030803 · Cited by 66
“[64] 2020 meta-analysis/13 studies (9 healthy cohort, 4 PD cohort) caffeine caffeine consumption resulted in a significantly lower rate of PD”
BackgroundThe role of nutrition on Parkinson’s disease: a systematic review
Bianchi, V. E., Rizzi, L., & Somaa, F. A. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2073107 · Cited by 67
“tion and PD remained significant after adjustment for education, smoking, and alcohol drinking [207].”
BackgroundThe Role of Diet in Parkinson’s Disease
Tosefsky, K. N., Zhu, J., Wang, Y. N., Lam, J. S. T., Cammalleri, A., & Appel‐Cresswell, S. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230264 · Cited by 57
The human lens: An antioxidant-dependent tissue revealed by the role of caffeine
Ruiß, M., Findl, O., & Kronschläger, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101664 · Cited by 46
Chen, J.-F., & Schwarzschild, M. A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.024 · Cited by 39
Wiesner, A., Paśko, P., & Kujawska, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211116142806 · Cited by 46
“According to the recent meta-analysis, regular coffee consumption might be associated with a lower risk of developing Parkinson’s disease and the slower rate of progression [53].”
Recent Updates on the Functional Impact of Kahweol and Cafestol on Cancer
Eldesouki, S., Qadri, R., Helwa, R. A., Barqawi, H. J., Bustanji, Y. K., Abu‐Gharbieh, E., & El‐Huneidi, W. (2022) · Molecules · doi:10.3390/molecules27217332 · Cited by 42
Ialongo, D., Tudino, V., Arpacioglu, M., Messore, A., Patacchini, E., Costi, R., Santo, R. D., & Madia, V. N. (2023) · Pharmaceuticals · doi:10.3390/ph16050730 · Cited by 44
Hou, C., Zeng, Y., Chen, W., Han, X., Yang, H., Ying, Z., Hu, Y., Sun, Y., Qu, Y., Fang, F., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac148 · Cited by 42
“, dementia and Parkinson’s disease) (5, 6).”
BackgroundSaccharomyces cerevisiae and Caffeine Implications on the Eukaryotic Cell
Ruta, L. L., & FARCASANU, I. C. (2020) · Nutrients · doi:10.3390/nu12082440 · Cited by 39
Chan, L., Hong, C., & Bai, C. (2021) · BMC Neurology · doi:10.1186/s12883-021-02411-5 · Cited by 36
Self-citationA COMPREHENSIVE REVIEW ON PHARMACOLOGICAL POTENTIALS OF CAFFEINE
Sharma, V. K., Sharma, A., Verma, K. K., Gaur, P. K., Kaushik, R., & Abdali, B. (2023) · Journal of Applied Pharmaceutical Sciences and Research · doi:10.31069/japsr.v6i3.04 · Cited by 43
de Lope, E. G., Loo, R. T. J., Rauschenberger, A., Ali, M., Pavelka, L., Marques, T. M., Gomes, C. P. C., Krüger, R., Glaab, E., Acharya, G., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00671-9 · Cited by 41
Gut microbiota and Parkinson’s disease
Wang, L., Cui, Y., Han, B., Du, Y., Salewala, K. S., Wang, S., Zhao, W., Zhang, H., Wang, S., Xu, X., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003318 · Cited by 38
Hutachok, N., Koonyosying, P., Pankasemsuk, T., Angkasith, P., Chumpun, C., Fucharoen, S., & Srichairatanakool, S. (2021) · Molecules · doi:10.3390/molecules26144169 · Cited by 34
Song, X., Singh, M. V., Lee, K. E., Vinayagam, R., & Kang, S. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212003 · Cited by 52
“[119] † Country: FIN: Finland, US: United States, Jp: Japan, Net: Netherlands, SG: Singapore, Tw: Taiwan.”
Mitigating Traumatic Brain Injury: A Narrative Review of Supplementation and Dietary Protocols
Conti, F., MCCUE, J., Dituro, P., Galpin, A. J., & Wood, T. R. (2024) · Nutrients · doi:10.3390/nu16152430 · Cited by 40
“…by the associated polyphenol intake—appears to be associated with a lower risk of neurodegenerative conditions at the population level [229–231], caffeine intake should be moderated in the symptomatic phase after TBI, as it may exacerbate some of its well-documented behavioural…”
BackgroundParkinson's disease: the nutrition perspective
Breasail, M. Ó., Smith, M. D., Tenison, E., Henderson, E. J., & Lithander, F. E. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003645 · Cited by 36
Zhao, J., Peng, Y., Lin, Z., & Gong, Y.-L. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100451 · Cited by 28
“Caffeine intake is associated with a reduced risk of PD, and there is evidence that PD progression is significantly reduced in individuals who consume caffeine [66].”
Coffee’s Impact on Health and Well-Being
Emadi, R. C., & Kamangar, F. (2025) · Nutrients · doi:10.3390/nu17152558 · Cited by 37
“A meta-analysis of these studies found that those who regularly consumed coffee/caffeine had a lower incidence of Parkinson’s disease [52], and patients with PD who regularly consumed coffee/caffeine had a lower rate of disease progression [52].”
Rees, J., Ryan, J. C., Laws, M., & Devine, A. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2233727 · Cited by 28
Coffee and Parkinson's disease
Asuku, A. O., Ayinla, M. T., Olajide, T. S., Oyerinde, T. O., Yusuf, J. A., Bayo-Olugbami, A. A., & Fajemidagba, G. A. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.001 · Cited by 21
Yoon, S. Y., Park, Y. H., Lee, H. J., Kang, D. R., & Kim, Y. W. (2021) · Neurology · doi:10.1212/wnl.0000000000012942 · Cited by 23
Coffee as a Source of Antioxidants and an Elixir of Youth
Kobylińska, Z., Biesiadecki, M., Kuna, E., Galiniak, S., & Mołoń, M. (2025) · Antioxidants · doi:10.3390/antiox14030285 · Cited by 29
“Emerging evidence suggests that moderate coffee consumption (1–4 cups per day) may be associated with a reduced risk of neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases [65–68].”
Exploring Risk and Protective Factors in Parkinson’s Disease
Beheshti, I. (2025) · Cells · doi:10.3390/cells14100710 · Cited by 22
“Additionally, consuming coffee is linked to a decreased likelihood of developing PD and slowing its advancement [223].”
Lifestyle factors and clinical severity of Parkinson’s disease
Gabbert, C., König, I. R., Lüth, T., Kasten, M., Grünewald, A., Klein, C., & Trinh, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-31531-w · Cited by 16
“Caffeine has previously been depicted to improve the motor deficits in PD or decelerate PD progression and ameliorate both motor and non-motor early symptoms 13,14 .”
What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs
Crotty, G. F., & Schwarzschild, M. A. (2022) · Neurology · doi:10.1212/wnl.0000000000200238 · Cited by 17
“, associations with “reduced risk”) for PD, with dozens of epidemiologic studies reproducibly finding caffeine intake predictive of a lower risk of developing the disease (in prospective cohort studies) or likelihood of having it (in case-control studies).(10,19,20) In addition, the biological plausibility that caffei…”
BackgroundEffect of caffeine and other xanthines on liver sinusoidal endothelial cell ultrastructure
Mao, H., Szafranska, K., Kruse, L. D., Holte, C. F., Wolfson, D. L., Ahluwalia, B. S., Whitchurch, C. B., Cole, L., Lockwood, G. P., Diekmann, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40227-0 · Cited by 19
Beverages – a scoping review for Nordic Nutrition Recommendations 2023
Sonestedt, E., & Lukic, M. (2024) · Food & Nutrition Research · doi:10.29219/fnr.v68.10458 · Cited by 22
The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease
Gabbert, C., Blöbaum, L., Lüth, T., König, I. R., Caliebe, A., Sendel, S., Laabs, B., Klein, C., & Trinh, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-65640-x · Cited by 15
Thorpe, H. H. A., Fontanillas, P., Pham, B. K., Meredith, J. J., Jennings, M. V., Courchesne‐Krak, N. S., Vilar‐Ribó, L., Bianchi, S. B., Mutz, J., Aslibekyan, S. W., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01870-x · Cited by 15
Curioni, C. C., da Silva, A. C. F., Pereira, A. D. S., & Mocellin, M. C. (2022) · Integrated science · doi:10.1007/978-3-030-85357-0_5 · Cited by 17
Medeiros, M. S., Schuh, A. F. S., Altmann, V., & Rieder, C. R. D. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619535 · Cited by 12
Lee, L. K., & Rodzi, N. A. R. M. (2022) · Antioxidants · doi:10.3390/antiox11081587 · Cited by 15
“A meta-analysis demonstrated that coffee intake can decrease the risk for developing PD [75].”
BackgroundRole of Caffeine in the Age-related Neurodegenerative Diseases: A Review
Pohanka, M. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220413103529 · Cited by 12
Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease
Saarinen, E. K., Kuusimäki, T., Lindholm, K., Niemi, K. J., Honkanen, E. A., Noponen, T., Seppänen, M., Ihalainen, T., Murtomäki, K., Mertsalmi, T. H., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26957 · Cited by 12
“15 Nevertheless, only 4 studies were included in the meta-analysis, and there was substantial heterogeneity in the parameters used to assess both caffeine consumption and PD progression in these studies, which limits the generalizability of their fi ndings.”
Aboutabl, M. E., Salman, A., el Din, A. A. G., & Maklad, Y. A. (2021) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-021-00678-9 · Cited by 10
Association of Caffeine Consumption and Brain Amyloid Positivity in Cognitively Normal Older Adults
Zheng, Y., Sun, J., Shi, L., Su, S., Chen, X., Wang, Q., Huang, Y., Wang, Y., Zhu, X.-M., Que, J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220591 · Cited by 10
“Caffeine consumption can affect multiple health outcomes [5], and has beneficial effects on various systems, including cardiology [6], endocrinology [7], psychiatry [8], and neurology [9].”
BackgroundKotit, S. (2023) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2023.13 · Cited by 18
Torres, A. S., Lee, J., Caporali, A., Semple, R. K., Horrocks, M. H., & MacRae, V. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010973 · Cited by 10
“Environmental factors thought to influence the development of PD include smoking, caffeine consumption and pesticide exposure [20–22].”
BackgroundA Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies
Rissardo, J. P., & Caprara, A. L. F. (2025) · Clinics and Practice · doi:10.3390/clinpract15030065 · Cited by 13
Carbone, M. G., Pagni, G., Tagliarini, C., Maremmani, I., & Maremmani, A. G. I. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22081171 · Cited by 15
“The evidence regarding caffeine’s influence on motor symptoms remains mixed; while some studies report benefits, others show limited or no effects [131,133–135].”
Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune
Goldman, S. M., Weaver, F. M., González, B., Stroupe, K. T., Cao, L., Colletta, K., Brown, E. G., & Tanner, C. M. (2024) · Movement Disorders · doi:10.1002/mds.29922 · Cited by 12
Caffeine content in filter coffee brews as a function of degree of roast and extraction yield
Lindsey, Z. R., Williams, J. R., Burgess, J. S., Moore, N. T., & Splichal, P. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-80385-3 · Cited by 15
“Previous studies have investigated possible links between consumption of coffee/caffeine and several health benefits, including lower risks of liver disease 2 , heart disease 3 , Parkinson’s disease 4 , Alzheimer’s disease 5 , type 2 diabetes 6 , depression 7 , and some forms of cancer 8 .”
Lifestyle medicine in Parkinson’s disease
Süß, P., Regensburger, M., Gassner, H., & Winkler, J. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03059-y · Cited by 6
“This was corroborated by a recent meta-analysis (Hong et al. 2020 ).”
Chang, B., Niu, C., & Jiang, Y. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111231 · Cited by 6
Grzelczyk, J., Budryn, G., Kołodziejczyk, K., & Ziętala, J. (2024) · Nutrients · doi:10.3390/nu16172823 · Cited by 8
“…Alzheimer’s and Parkinson’s diseases, type 2 diabetes, and metabolic orders [62,63]. with fruit pulps of melon (92.11%, IC = 3.80 mg/mL), apple (84.55%, IC = 4.14 mg/mL), and red wine (88.33% IC = 3.96 mg/mL) showed the highest enzyme inhibition activity ( α -amylase 0.5 mg/mL, 10 µ mol/mL).”
BackgroundInfluentialPrevention of Parkinson’s Disease: From Risk Factors to Early Interventions
Ng, M. G., Chan, B. J. L., Koh, R. Y., Ng, K. Y., & Chye, S. M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230616092054 · Cited by 8
Family History of AD /Dementia, Polygenic Risk Score for AD , and Parkinson's Disease
Xu, X., Li, Y., Wang, J., Cao, Y., Feng, C., Guo, Y. H., Zong, G., Sun, L., & Gao, X. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13919 · Cited by 7
Peng, R. Y., Lan, M., Zhang, Y., Zhang, S., Yu, B., Xu, Y., Li, S., Liu, Z., & Kang, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1690881 · Cited by 12
Charidemou, E., Andreou, E. P., & Papaneophytou, C. P. (2026) · Biomolecules · doi:10.3390/biom16060867 · Cited by 8
Role of neuron specific enolase as a biomarker in Parkinson’s disease
Dutta, R. (2021) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001052 · Cited by 5
Hong, C., Chan, L., & Bai, C. (2023) · Nutrients · doi:10.3390/nu15030699 · Cited by 5
“Error in Figure/Table In the original publication [1], there were some mistakes in Tables 1 and 2 and Figures 2 and 3 as published.”
BackgroundSelf-citationCaffeine: A Neuroprotectant and Neurotoxin in Traumatic Brain Injury (TBI)
Sharma, B., Agriantonis, G., Dawson-Moroz, S., Brown, R., Simon, W., Ebelle, D., Chapelet, J., Cardona, A., Soni, A., Siddiqui, M., et al. (2025) · Nutrients · doi:10.3390/nu17111925 · Cited by 7
Koffein, Schokolade und Adenosin A2A Rezeptorantagonisten in der Behandlung des Parkinson Syndroms
Reichmann, H. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1785-3632 · Cited by 6
“Geriatr Gerontol Int 2014; 14: 430–439 [31] Hong CT, Chan L, Bai CH.”
BackgroundCoffee and Caffeine Consumption for Human Health
Abalo, R. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-5500-3 · Cited by 4
Mak, J. K. L., Chau, Y.-P., Tan, K. C. B., Kung, A. W.-C., & Cheung, C. (2024) · Nutrients · doi:10.3390/nu16203536 · Cited by 5
Exploring the Role of Food and Food-Related Compounds in Parkinson’s Disease
Trezzi, I., Rizzo, G., Giampieri, F., Battino, M. A., & Baroni, L. (2026) · Foods · doi:10.3390/foods15030514 · Cited by 6
“Caffeine intake may also slow down disease progression, especially when combined with physical activity [127,128].”
Koníčková, D., Menšíková, K., Plíhalová, L., & Kaňovský, P. (2024) · Nutrition Research Reviews · doi:10.1017/s0954422424000349 · Cited by 5
“The different abundances and contents of CAF are studied because of its many effects on the organism (genetic polymorphism, sex and metabolic heterogeneity) (12) .”
InfluentialIjaz, N., Sardar, M., & Mehak, H. S. (2021) · FRONTIERS IN CHEMICAL SCIENCES · doi:10.52700/fcs.v2i1.18 · Cited by 4
“…energy boosting drink, However, research has shown that it results in many other health boosting effects also, for example lower contracting risk of Type-2-diabetes (Cornelis 2020), liver carcinoma, cirrhosis and fibrosis (Inoue and Tsugane 2019) and heart failure (Messina, Zannella et al. 2015).”
BackgroundCaffeine consumption and Parkinson’s disease: a mini-review of current evidence
Victorino, D. B., Guimarães‐Marques, M., & Nehlig, A. (2021) · Revista Neurociências · doi:10.34024/rnc.2021.v29.12641 · Cited by 4
Adenosin A2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?
Jost, W. H., & Tönges, L. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1771-6225 · Cited by 2
“[23] 2020 Metaanalyse aus 13 Studien (9 gesunde Kohorten, 4 ParkinsonKohorten) Koffein Koffeinkonsum war mit geringerem Risiko für die Entwicklung der Parkinson-Erkrankung verbunden”
BackgroundCoffee and multiple sclerosis (MS)
Ghallab, Y. K., Elassal, O. S., & Mina, R. G. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.009 · Cited by 2
Pirovano, E., Marino, F., Rossi, E. G., Gennari, A., Rasini, E., Uslenghi, M., Figueira, I., Iacoviello, L., Ferrari, M., & Cosentino, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101946 · Cited by 5
Huang, M., & Zhang, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98820-9.00003-x · Cited by 1
Coffee and the Brain: A Comprehensive Review of Its Neurological and Psychiatric Effects
Pareek, V., Shah, S., Sharma, B., Kumar, S., & Sharma, L. K. (2024) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_53_23 · Cited by 1
Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson’s Disease
Dong, X., Zheng, Y., Tan, E. T. Y., Sun, Q. Y., Xiao, B., Tan, E.-K., Wu, Y., & Zhou, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010016 · Cited by 1
“Notably, prior metabolomic analyses have identified diminished caffeine and caffeine-metabolite levels as biomarkers of increased PD vulnerability [7,25,37,38], with effects more pronounced in LRRK2 -associated PD than in idiopathic cases [14,16,39].”
Schaeffer, E., Becktepe, J. S., Brockmann, K., Eggers, C., Gülke, E., Kalbe, E., Rattay, T. W., Tönges, L., Warnecke, T., Zeuner, K. E., et al. (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00488-2 · Cited by 1
“Finally, there is substantial evidence that specific con - sumables – i.e. caffeine and tea intake - have protective effects [28, 29].”
The medical use of Málaka wine and cola nuts in late 19th/early 20th century Greece
Tsoucalas, G., & Vladimiros, L. (2024) · Deltos. · doi:10.12681/dj.38116 · Cited by 1
Coffee and Caffeine Consumption for Human Health
Del Coso, J. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-629-4 · Cited by 1
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists
Simola, N., Pinna, A., Frau, L., Costa, G., Marongiu, J., Parekh, P., Serra, M., & Morelli, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_103 · Cited by 1
Thorpe, H. H. A., Fontanillas, P., Pham, B. K., Meredith, J. J., Jennings, M. V., Courchesne‐Krak, N. S., Vilar‐Ribó, L., Bianchi, S. B., Mutz, J., Elson, S. L., et al. (2023) · medRxiv · doi:10.1101/2023.09.09.23295284 · Cited by 1
Jbaily, H. (2023) · Preprints.org · doi:10.20944/preprints202312.2099.v1
The effect of coffee drinking on frequency of selected chronic diseases
Pelechová, N., Rimárová, K., & Diabelková, J. (2020) · Hygiena · doi:10.21101/hygiena.a1765
Effect of Coffee, Tobacco, and Alcohol on Parkinson’s Disease
Seol, W., Kim, H. J., & Son, I. (2021) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2021.3.3
Parkinson’s Disease and Eating and Weight Disorders
Cuzzolaro, M., & Melchionda, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-81174-7_31
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists
Simola, N., Pinna, A., Frau, L., Costa, G., Marongiu, J., Parekh, P., Serra, M., & Morelli, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_103-1 · Cited by 1
Paiva, T. L., Santos, G. F., Coutinho, J. O. B., Mendonça, M. M. M., Dutra, D. S., Leite, J. A. D. M., Rigueira, J. M. L., Mazzieiro, G. P., Ferreira, L. C. C., & de Araújo, B. C. (2022) · Research Society and Development · doi:10.33448/rsd-v11i8.31424 · Cited by 2
Rodrigues, L. S., Targa, A., Noseda, A. C. D., Ilkiw, J. L., Fagotti, J., Kmita, L. C., Dominico, P., Dorieux, F. W. C., Silveira, P. L. S., Cóppola-Segovia, V., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1991814/v1
The Coffee Revolution: From Politics to Optimized Health
Barag, S., Viehoever, A. R., Kawashima, T., Ko, A., Sanchez, D., Stull, C., & Nadeau, D. (2023) · Journal of the Osteopathic Family Physicians of California · doi:10.58858/010102
Norouzy, A., Mohamadinarab, M., & Kalayeh, H. M. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00046-5
Lapa, J. D. D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-23102023-132448 · Cited by 1
Atividade profilática da cafeína no controle da doença de Parkinson
Freitas, S. R. D. N., de Lima, M. D. S. F., & Barros, D. P. D. O. (2024) · Revista Brasileira de Pesquisa em Saúde/Brazilian Journal of Health Research · doi:10.47456/rbps.v25i4.40561
Kuszneruk, J., Chawrylak, K., Kłusek, M., Kubas, M., & Krzemińska, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.18.53301 · Cited by 1
Genetic methods to evaluate evidence for causal effect of coffee on health
Pham, K., & Hyppönen, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13868-3.00040-5
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Inflammatory Roads to Parkinson’s Disease
Anisman, H., Hayley, S. P., & Kusnecov, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00015-6
The impact of coffee consumption on human health
Markowska, A., Pietras, J., Twardawa, D., & Markowska, J. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0025
Metadata
- Authors
- Hong, C. T., Chan, L., & Bai, C.-H.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University Hospital (TW)
- Corresponding author
- Chan, Lung
- Bai, Chyi-Huey
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-06-22
- Volume
- 12
- Issue
- 6
- Pages
- 1860
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC7353179
- OpenAlex
- W3036886081
- Cited by
- 113
- References
- 57
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 29 · 2023: 17 · 2022: 18 · 2021: 18 · 2020: 6
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-22)
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- caffeine, Parkinson's disease, coffee consumption, disease risk, disease progression, dyskinesia, motor fluctuations, neuroprotection
- MeSH terms
- Caffeine, Coffee, Humans, Levodopa, Parkinson Disease, Cohort Studies, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.